Loading
TAMPA — Romark Laboratories raised $23.1 million in an equity offering, a filing with the Securities and Exchange Commission shows. Romark is a pharmaceutical company that develops molecular treatments for infectious diseases and cancers.
The offering attracted 155 investors, the filing shows. Romark paid $2.4 million, or 10% of gross proceeds plus $75,000, in commission on the offering, giving the company just over $20 million in net proceeds from the deal. Tampa-based GunnAllen Financial Inc. was one of three firms to receive sales compensation on the deal.
In April 2010, a Romark drug that treats Hepatitis-C succeeded in a clinical trial.
Your free article limit has been reached this month.
Subscribe now for unlimited digital access to our award-winning business news.
Join thousands of executives who rely on us for insights spanning Tampa Bay to Naples.
